2021 has been a challenging year for life sciences organizations amidst the COVID-19 pandemic. There has been an ever-increasing volume of safety cases with diverse sources of safety information, better public awareness on safety of medicinal products, and unprecedented demand for information and responses. As a result, the pharmacovigilance approach has been forced to evolve, innovate, and adopt efficient solutions, and leverage smart technologies to operate and manage patient safety data effectively as well as efficiently.
At TCS ADD Safety, we were pleased to host an industry-mapped panel which focused its discussion on key areas that enable seamless adoption of smart pharmacovigilance and the role of AI in improving patient safety. In addition, our panelists at the virtual event also discussed how to enable safety case processing in pharmacovigilance through technology-led approach. Shared below is the high-level snapshot of thematic areas that were discussed at the virtual event.
- Leveraging AI as a scalable approach to handle safety case volume
- Handling complexities in safety reports with AI
- Achieving compliance when using artificial intelligence in pharmacovigilance
- Increasing efficiencies with enhanced quality and accuracy
- Sharing real life experiences of enabling artificial intelligence in pharmacovigilance – lessons learnt and way forward
We are happy to have onboarded, revered panelists who have been responsible for transforming pharmacovigilance in their organizations through industry-first initiatives.
- Michael Murphy, Executive Director and Head of Pharmacovigilance Operations, Amgen
- Bharathish Rao, Associate Director, Patient Safety Systems (CMO Organization), AstraZeneca
- Arpita Bhowmick, Global Director, Omni Channel Contact Center Technology, Moderna
- Dr. Mangesh Kulkarni, Medical Director and Head of PV, TCS
- [Moderator] Dr. Alejandra Guerchicoff, Industry Leader, TCS ADD Safety, TCS
For more info on TCS ADD Safety, visit